Biodesix, Inc. (BDSX)

Over the past six months, Biodesix's stock price has experienced significant volatility. Preliminary Q4 and full-year 2025 results were announced in January 2026. Q3 2025 financial results were reported in November 2025. A one-for-twenty reverse stock split was executed in September 2025. Q2 2025 results were reported in August 2025. Earlier in 2025, the company experienced a revenue miss in Q1, leading to a reduction in revenue guidance for the year.

The provided information does not explicitly detail demand seasonality for Biodesix, Inc.'s products and services. Demand might be relatively consistent throughout the year, driven by ongoing medical needs rather than strong seasonal fluctuations. The company's efforts to expand its commercial footprint into primary care networks for lung nodule management indicate a continuous market opportunity.

Biodesix, Inc. is a diagnostic solutions company focused on improving clinical decisions for patients with lung disease, particularly lung cancer. The company operates within the Healthcare sector and the Medical Diagnostics & Research industry, leveraging advanced proteomic and genomic technologies to identify actionable biomarkers. Biodesix offers a portfolio of proprietary diagnostic tests, including blood-based lung tests and diagnostic solutions and services to biopharmaceutical companies. The company also previously offered COVID-19 tests under its WorkSafe testing program.

Biodesix, Inc. is headquartered in Louisville, Colorado, United States and operates as a data-driven diagnostic solutions company in the United States.

Biodesix's brand reputation is reflected in its financial performance and strategic developments. Positive developments include strong preliminary Q4 and full-year 2025 results and the expansion of their commercial strategy into primary care. Challenges include the earlier revenue miss in Q1 2025 and subsequent reduction in revenue guidance, which likely had a temporary negative impact on investor confidence.

Biodesix, Inc. has a mix of institutional and individual owners. Major institutional shareholders include Vanguard Total Stock Market Index Fund Investor Shares, Vanguard Extended Market Index Fund Investor Shares, Telemark Asset Management, LLC, Fidelity Extended Market Index Fund, and Vanguard Group Inc. Lawrence T. Kennedy Jr. is the largest individual shareholder. Other significant individual insider owners include Matthew Strobeck, Jack W. Schuler, Charles M. Watts, John Patience, Hany Massarany, and Jon Faiz Kayyem.